A real-world analysis of adherence, biochemical outcomes, and healthcare costs in patients treated with rosuvastatin/ezetimibe as single-pill combination vs. free combination in Italy.

Alberto ZambonEvangelos LiberopoulosMelania DovizioChiara VeronesiLuca Degli EspostiLeopoldo Pérez de Isla

Published in: European heart journal open (2024)

This real-world analysis in dyslipidaemic patients found that treatment with ROS/EZE as SPC resulted in better adherence, higher chances of reaching lipid goals, and cost savings over FCT, in all cardiovascular risk categories.

Keyphrases

healthcare
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
cell death
prognostic factors
dna damage
public health
adipose tissue
metabolic syndrome
patient reported outcomes
combination therapy
health insurance
social media
replacement therapy
affordable care act